Therapeutic activity of 1-beta-D-arabinofuranosylcytosine conjugates of lipids in WEHI-3B leukemia in mice

Exp Hematol. 1989 May;17(4):364-7.

Abstract

Two new conjugates of 1-beta-D-arabinofuranosylcytosine (ara-C) and lipids were tested for therapeutic activity in myelomonocytic WEHI-3B leukemia in mice. Both conjugates were superior to equimolar mixtures of their respective parent compounds and to ara-C alone. IP treatment was found effective after either IP or IV transplantation of the leukemia. The thioether-linked lipid conjugate ara-CDP-D,L-PTBA showed considerably higher efficacy than the ester-linked lipid conjugate ara-CDP-L-dipalmitin. The optimal therapeutic regimen of ara-CDP-D,L-PTBA consisted of 60 mg/kg given IP qd 1-5 after transplantation of the WEHI-3B leukemia.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use*
  • Cell Division / drug effects
  • Cell Line
  • Cytarabine / administration & dosage
  • Cytarabine / analogs & derivatives*
  • Cytarabine / therapeutic use
  • Drug Administration Schedule
  • Female
  • Injections, Intraperitoneal
  • Leukemia, Myeloid / drug therapy*
  • Mice
  • Mice, Inbred BALB C
  • Neoplasm Transplantation

Substances

  • Antineoplastic Agents
  • Cytarabine
  • 1 beta-D-arabinofuranosylcytosine 5'-diphosphate-L-1,2 dipalmitin
  • 5'-palmitoyl cytarabine